Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Introduction: Follicular lymphoma (FL) is a heterogeneous disease. Early progression after initial treatment with chemoimmunotherapy, or POD24, occurs in approximately 20% of patients and strongly predicts poor outcomes. There is no standard treatment approach for patients with high-risk, relapsed or refractory (R/R) FL (high-risk subgroups in Table). Novel treatment options are needed to improve efficacy in patients with high unmet need.
Background: Systemic T-cell lymphoma (TCL) is heterogeneous group of hematological malignancies with extremely poor prognosis. The prognosis of relapsed/ progressed disease is much worse, but there are sporadic data about this group of patients only. We focused on the most frequent subsets ALCL, PTCL-NOS and AITL/TFH-TCL) representing around 70% of all systemic T-cell lymphoma.
Background: Aggressive non-Hodgkin's lymphoma (NHL) comprises 44% of all NHL, and diffuse large B-cell lymphoma (DLBCL) is the most common subtype. Anthracycline-based regimens are the standard of care for front-line therapy. There is currently no standard treatment for relapsed/refractory (R/R) aggressive NHL beyond second-line for patients who are not transplant-eligible. Pixantrone is a novel aza-anthracenedione designed to have less cardiac toxicity than the anthracyclines.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.